Status:
RECRUITING
Feasibility Performance Study of ABL90 FLEX PLUS HEM
Lead Sponsor:
Radiometer Medical ApS
Collaborating Sponsors:
Bispebjerg Hospital
Conditions:
Hemolysis
Eligibility:
All Genders
18+ years
Brief Summary
This feasibility performance study evaluates the ABL90 FLEX PLUS HEM device for its analytical performance in a clinical setting. The study aims to evaluate the performance of the hemolysis detection ...
Detailed Description
The study is designed to assess the feasibility and performance of the ABL90 FLEX PLUS HEM device in a clinical environment. It will involve testing whole blood samples using the device and comparing ...
Eligibility Criteria
Inclusion Criteria:
-
Subject must be 18 years of age or older
-
Informed consent is obtained:
- Directly from the subject, if they are competent and able to understand the provided information and voluntarily agree to participate, or
- If the subject is temporarily incapacitated and unable to provide informed consent at the time of sample collection, written informed consent will be obtained from the subject's legally designated representative (LDR). when the subject regains capacity after enrollment, they will be informed of study inclusion and given the opportunity to withdraw consent.
-
Subject evaluated as suitable according to the protocol and for the study by the principal investigator or designee.
Exclusion Criteria:
- Subject where sample collection is evaluated by PI or designee to impose unnecessary risk.
- Subject with an invalid written informed consent or who has withdrawn consent.
- Subject with known pregnancy or who is breastfeeding.
Key Trial Info
Start Date :
August 4 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 10 2026
Estimated Enrollment :
95 Patients enrolled
Trial Details
Trial ID
NCT07345091
Start Date
August 4 2025
End Date
June 10 2026
Last Update
January 15 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bispebjerg Hospital
Copenhagen, NV, Denmark, 2400